Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma

Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor with a short survival time arising from the mesothelial cells of the pleura. Soluble mesothelin-related peptide (SMRP), osteopontin or EFEMP1 (Fibulin-3) are well described biomarkers for malignant mesothelioma with moderate sensitivity and specificity. In this study, we characterized the expression of glycodelin, a marker for ...

متن کامل

MESOMARK: a potential test for malignant pleural mesothelioma.

BACKGROUND Soluble mesothelin-related peptides (SMRP)have been reported to be potential biomarkers for malignant pleural mesothelioma (MPM). We report analytical and preliminary clinical studies of MESOMARK, a quantitative assay for SMRP. METHODS The MESOMARK assay is a 2-step immunoenzymatic assay in an ELISA format with a 6-point calibration curve (0-32 nmol/L). We assessed analytical impre...

متن کامل

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up R. A. Stahel, W. Weder, Y. Lievens & E. Felip On behalf of the ESMO Guidelines Working Group* Clinic and Policlinic of Oncology; Department of Thoracic Surgery, University Hospital of Zürich, Zürich, Switzerland; Radiation Oncology Department, Leuven University Hospitals, Leuven, Belgium; Me...

متن کامل

Malignant pleural mesothelioma: ESMOClinical Practice Guidelines for diagnosis, treatment and follow-up†

P. Baas1,2, D. Fennell3, K. M. Kerr4, P. E. Van Schil5, R. L. Haas6 & S. Peters7, on behalf of the ESMO Guidelines Committee* Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam; The Academic Medical Center, Amsterdam, The Netherlands; Department of Medical Oncology, University of Leicester, Leicester; Department of Pathology, University of Aberdeen, Aberdeen, UK; Depar...

متن کامل

Radiotherapy for malignant pleural mesothelioma.

BACKGROUND Malignant pleural mesothelioma is a relatively uncommon disease, but the incidence is increasing and is expected to peak in many developed countries in the next two decades. The management of patients with malignant mesothelioma is controversial. Very few patients are suitable for any potentially curative treatment and the effectiveness of radical therapy with surgery, radiotherapy a...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Oncotarget

سال: 2016

ISSN: 1949-2553

DOI: 10.18632/oncotarget.12474